Glycoprotein Acetyls (GlycA) as a Biomarker of Systemic Inflammation in Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Introduction

Patients presenting with nonspecific inflammatory symptoms are often evaluated across multiple specialties, yet only a minority receive a definitive diagnosis of systemic lupus erythematosus (SLE) or antiphospholipid syndrome (APS). It has long been recognized that SLE is associated with a wide spectrum of related conditions. The clinical heterogeneity, fluctuating disease activity, and limitations of traditional laboratory markers frequently delay diagnosis. Consequently, there is a need for greater awareness among primary care physicians, along with reliable check-up guidelines, to better recognize systemic inflammation and enable earlier identification of these complex disorders.

Glycoprotein acetyls (GlycA) is an emerging biomarker derived from nuclear magnetic resonance (NMR) spectroscopy that reflects systemic inflammation through the quantification of N-acetyl methyl group signals on circulating glycosylated acute-phase proteins. These proteins include α1-acid glycoprotein, haptoglobin, α1-antitrypsin, and others that increase during inflammatory states. Unlike traditional single-analyte markers, GlycA represents a composite signal integrating multiple inflammatory pathways, making it particularly valuable in complex autoimmune diseases such as Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS).

At a biochemical level, GlycA captures both the concentration and glycosylation patterns of acute-phase proteins. These glycosylation changes are not merely passive reflections of inflammation but are actively involved in modulating immune responses, endothelial interactions, and protein stability. As a result, GlycA functions as a robust and stable indicator of chronic inflammatory burden rather than transient inflammatory spikes.

GlycA in Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus is a heterogeneous autoimmune disease characterized by fluctuating disease activity, multisystem involvement, and complex immunopathology. Accurate monitoring of disease activity is critical, yet traditional biomarkers often fail to fully capture the chronic and multifaceted nature of inflammation in lupus. GlycA has emerged as a promising solution to this limitation.

One of the most significant features of GlycA in SLE is its strong association with disease activity. Patients with active lupus consistently demonstrate elevated GlycA levels compared to those in remission or healthy individuals. Importantly, GlycA correlates with established disease activity indices such as the SLEDAI-2K, suggesting that it reflects clinically meaningful inflammatory processes. Unlike C-reactive protein (CRP), which may remain normal in lupus despite active disease due to interferon-mediated suppression, GlycA provides a more reliable measure of ongoing systemic inflammation.

GlycA is particularly valuable in the context of lupus nephritis, one of the most severe complications of SLE. Studies have shown that GlycA levels are significantly higher in patients with proliferative lupus nephritis compared to those with non-proliferative forms. This distinction is clinically critical, as proliferative nephritis requires more aggressive immunosuppressive treatment and carries a higher risk of long-term renal damage. GlycA therefore serves as a non-invasive biomarker that may help stratify disease severity and reduce reliance on repeated kidney biopsies. Furthermore, GlycA levels tend to rise during renal flares, indicating its usefulness in monitoring disease progression and treatment response.

Beyond renal involvement, GlycA reflects broader inflammatory and metabolic dysregulation in lupus. It correlates with other inflammatory markers such as high-sensitivity CRP (hsCRP), erythrocyte sedimentation rate (ESR), and neutrophil counts, as well as metabolic parameters like triglyceride levels. This relationship highlights the intersection between inflammation and altered lipid metabolism in SLE, often referred to as the “lipid paradox,” where traditional lipid measures underestimate cardiovascular risk.

Notably, the association between GlycA and disease severity appears to be independent of confounding factors such as corticosteroid use and standard laboratory parameters. This independence strengthens its role as a true marker of disease-driven inflammation rather than treatment effects or nonspecific physiological variation.

GlycA in Antiphospholipid Syndrome (APS)

Antiphospholipid Syndrome is a thrombo-inflammatory disorder characterized by the presence of antiphospholipid antibodies, particularly those directed against β2-glycoprotein I. These antibodies promote a hypercoagulable state leading to arterial and venous thrombosis, pregnancy morbidity, and chronic vascular complications. While research specifically focused on GlycA in primary APS remains limited, its relevance is increasingly recognized, especially in patients with APS secondary to lupus.

The pathophysiology of APS involves a complex interplay between immune activation, endothelial dysfunction, complement activation, and coagulation pathways. GlycA is well suited to capture this multifactorial process because it reflects chronic, low-grade systemic inflammation that underlies thrombotic risk. Elevated GlycA levels in APS likely indicate persistent vascular inflammation and immune activation, both of which contribute to clot formation.

One of the most clinically significant roles of GlycA in APS is its ability to predict cardiovascular risk. Patients with APS and lupus are at markedly increased risk of cardiovascular disease, including myocardial infarction and stroke. Traditional risk factors do not fully explain this increased risk, making additional biomarkers essential. GlycA has been validated as a predictor of cardiovascular events in various populations, and its elevation in autoimmune disease suggests it may provide critical insight into inflammation-driven atherogenesis and thrombosis.

GlycA also appears to be linked to complement system activity, particularly in lupus-associated APS. Elevated GlycA levels often coincide with reduced complement components (such as C3 and C4), reflecting complement consumption during active inflammation. This relationship supports the concept of a shared pathway connecting immune complex formation, complement activation, endothelial injury, and thrombosis. In this context, GlycA may serve as a bridge biomarker linking inflammation and vascular damage.

Clinically, elevated GlycA may correspond with manifestations of vascular injury such as livedo reticularis, microvascular thrombosis, and neurological complications. Although not yet a standard diagnostic tool in APS, it holds promise as a marker for identifying patients at high risk for thrombotic events and long-term vascular complications.

Comparison with Traditional Inflammatory Markers

GlycA offers several advantages over conventional inflammatory markers used in SLE and APS.

One of its most important features is stability. CRP levels can fluctuate rapidly in response to minor infections or transient inflammatory stimuli, making it difficult to distinguish chronic disease activity from acute, unrelated events. In contrast, GlycA exhibits low intra-individual variability over time, providing a more consistent reflection of sustained inflammation.

Another key advantage is its composite nature. While CRP represents a single acute-phase protein, GlycA integrates signals from multiple glycosylated proteins involved in the inflammatory response. This allows it to capture a broader and more nuanced picture of immune system activity, particularly in diseases where multiple inflammatory pathways are simultaneously active.

GlycA also appears to be relatively independent of demographic and physiological variables such as age, sex, and body mass index. This contrasts with many traditional biomarkers that can be influenced by these factors, potentially confounding their interpretation. As a result, GlycA may provide a more specific measure of disease-related inflammation.

Importantly, GlycA and CRP do not measure identical aspects of inflammation. In autoimmune diseases, they often provide complementary information. For example, CRP may remain low in lupus due to interferon signaling, while GlycA remains elevated, reflecting ongoing inflammatory activity. This distinction underscores the value of incorporating GlycA into a broader biomarker panel.

Clinical Implications and Future Directions

The integration of GlycA into clinical practice has the potential to significantly improve the management of SLE and APS. Its ability to reflect chronic inflammation, predict disease activity, and identify high-risk patients makes it a valuable tool for personalized medicine.

In lupus, GlycA may help clinicians detect disease flares earlier, monitor treatment response more accurately, and assess the severity of organ involvement, particularly in lupus nephritis. In APS, it may contribute to better risk stratification for thrombotic and cardiovascular events, guiding preventive strategies and therapeutic decisions.

Future research is likely to focus on standardizing GlycA measurement, establishing reference ranges in autoimmune populations, and integrating it into clinical algorithms alongside existing biomarkers. Longitudinal studies will be essential to determine its predictive value over time and its responsiveness to therapeutic interventions.

Conclusion

Glycoprotein acetyls (GlycA) represents a significant advancement in the assessment of systemic inflammation in autoimmune diseases. In Systemic Lupus Erythematosus, it serves as a reliable marker of disease activity, a non-invasive indicator of lupus nephritis severity, and a reflection of metabolic-inflammatory interactions. In Antiphospholipid Syndrome, it captures the underlying thrombo-inflammatory state and provides insight into cardiovascular risk and endothelial dysfunction.

Its stability, composite nature, and independence from confounding factors distinguish it from traditional biomarkers such as CRP. As research continues to expand, GlycA is poised to become an important component of modern autoimmune disease management, offering a more comprehensive and clinically relevant view of inflammation and its consequences.

References:

GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk https://link.springer.com/article/10.1186/s12967-017-1321-6

Glycoprotein Acetyls Is a Novel Biomarker Predicting Cardiovascular Complications in Rheumatoid Arthritis https://pmc.ncbi.nlm.nih.gov/articles/PMC11173129/

GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk
https://pmc.ncbi.nlm.nih.gov/articles/PMC5658936/#:~:text=Therefore%2C%20GlycA%20may%20be%20used,3)%20as%20an%20aid%20in

GlycA: A New Biomarker for Systemic Inflammation and Cardiovascular Disease (CVD) Risk Assessment https://pmc.ncbi.nlm.nih.gov/articles/PMC7194207/

GlycA: A Biomarker of Chronic Inflammation https://precisionhealthreports.com/biomarkers/glyca

Insights into Pathophysiological Pathways in ME/CFS Through Genetic Correlation and Mendelian Randomization https://www.researchsquare.com/article/rs-9363637/v1

Search This Blog

Q and A: about health and research